Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Takeda Pricing Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Our Pipeline
Therapeutic Areas
Patient Services & Assistance
U.S. Product List
Independent Medical Education Grants
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Takeda Unveils Newly Renovated Building at 500 Kendall Street
How Our Los Angeles Site Pursues Energy Independency and Helps Takeda Become a Carbon-zero Operation
Progress Promise and a Path Forward A Look Inside Takedas Wave 1 Pipeline
Partnerships as Catalysts for Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Caring
A Family Affair How Takeda Cares
Answering the Call How Takeda Cares
Advancing Health Equity Built on Trust
Takeda Redoubles DEI Efforts With Insight Action
How Takeda is thinking about value-based arrangements with payers
Building trust between the pharma industry and Black and Brown communities
Strengthening the communities where we live and work
Heritage
Corporate Responsibility
Purpose-led Sustainability
Sustainability underpins all we do at Takeda to help solve key societal challenges and create value for society.
Learn more
Patients
Patient Services and Assistance
Diversity, Equity & Inclusion in R&D
People
Diversity, Equity & Inclusion
Commitment to Community
Careers
Planet
Environmental Stewardship
Ethics and Compliance
Statements & Disclosures
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
Statements
NATPARA Updates
COVID-19 Updates
News Releases
Enter
All
Last 12 months
2017
2016
2015
2014
2013
2012
2009
2008
2007
2005
2004
2003
2002
2000
December 2021
December 2, 2021
12/2/2021
Takeda’s LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
November 2021
November 30, 2021
11/30/2021
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
November 4, 2021
11/4/2021
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis Improve Access to Care for Patients with Rare Disease
September 2021
September 28, 2021
9/28/2021
Seramount Names Takeda as One of the 2021 100 Best Companies and Best Companies for Dads
June 2021
June 14, 2021
6/14/2021
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Adult Prophylactic Use of VONVENDI® [von Willebrand factor (Recombinant)]
March 2021
March 1, 2021
3/1/2021
The Children’s National Hospital Rare Disease Institute and Takeda Partner to Standardize Care for Patients With Rare Diseases
December 2020
December 15, 2020
12/15/2020
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
December 2, 2020
12/2/2020
TAKEDA FURTHER ENABLES HEMOPHILIA A PERSONALIZED CARE WITH LAUNCH OF MYPKFIT® SOFTWARE FOR ADYNOVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED]
1
2
3
4
5
TOP
Close
